Your Newborn's Health Starts with Screening. Here's What You Need to Know.

BRCA1 is your cells’ primary DNA repair machine. When DNA gets damaged,from sun exposure, age, or random cellular errors,BRCA1 springs into action to fix the break. Without working BRCA1, those DNA breaks accumulate, cells mutate, and cancer risk skyrockets. This is why BRCA1 is called a tumor suppressor.

BRCA1 pathogenic variants are rare,roughly 1 in 400 people in the general population carries a mutation. But when someone does, their lifetime breast cancer risk jumps to 55-72%, and ovarian cancer risk climbs to 39-46%. These aren’t small increases. These are dramatic shifts in baseline risk that reshape medical decision-making.

For a newborn, finding a BRCA1 variant doesn’t mean they have cancer now. It means they will need different screening, risk assessment, and possibly preventive strategies as they grow. If your daughter carries BRCA1, she might choose earlier mammograms, MRI screening, or even preventive surgery. If your son carries it, he has elevated male breast cancer and prostate cancer risk,less dramatic than female risk but still significant.

BRCA2 works alongside BRCA1 to repair DNA damage, but it handles a slightly different set of breaks. Both are essential. BRCA2 also suppresses tumors by maintaining genetic stability,but when it fails, cancer risk patterns shift slightly from BRCA1.

BRCA2 variants are even rarer than BRCA1, at roughly 1 in 800 people. When present, lifetime breast cancer risk reaches 45-69%, and ovarian cancer risk rises to 11-17%. But BRCA2 also elevates male breast cancer risk far more than BRCA1 does, and it increases pancreatic and prostate cancer risk across the board.

In a newborn, BRCA2 means the same long-term planning as BRCA1, but the surveillance strategy might emphasize different cancer types. Males with BRCA2 need breast awareness despite lower absolute risk. Pancreatic cancer screening and prostate monitoring become relevant in adulthood.

MTHFR converts folate (vitamin B9) into its active form, methylfolate, which your cells use to build DNA, repair it, and produce neurotransmitters. It’s a foundational gene for development, especially in newborns and growing children. Nearly every biological process depends on what MTHFR makes.

The MTHFR C677T variant is incredibly common,roughly 40% of people of European ancestry carry at least one copy. People with two copies of the T allele have 40-70% reduced MTHFR enzyme activity. That means their cells struggle to convert dietary folate into usable methylfolate, no matter how much folate they eat.

In a newborn, MTHFR C677T variants don’t cause immediate illness, but they do increase risk for neural tube defects if the mother was folate-deficient during pregnancy, and they can slow neurodevelopment if folate intake remains suboptimal through childhood. Later in life, MTHFR variants are associated with elevated homocysteine,an independent cardiovascular risk factor,and may increase susceptibility to certain mood or neurological conditions.

F5 encodes Factor V, a critical blood clotting protein. Without Factor V, blood won’t coagulate and you can bleed to death. With normal Factor V, your blood clots appropriately when you’re injured but stays liquid in your vessels at rest,a delicate balance.

The Factor V Leiden variant (R506Q) is the most common inherited thrombophilia in people of European ancestry, present in roughly 5% of the population. People with one copy of Factor V Leiden have a 4-8x increased risk of deep vein thrombosis (DVT) and pulmonary embolism (PE). For someone taking oral contraceptives or undergoing surgery, that risk climbs 80-fold.

In a newborn, Factor V Leiden doesn’t cause clotting in infancy. But it’s critical information before adolescence, because once your child reaches teenage years and might consider hormonal contraception, that variant information becomes lifesaving. Before any surgery, anesthesia team needs to know. If they ever become immobilized for weeks, anticoagulation might be considered. A simple newborn screening result that flags F5 Leiden guides medical decisions for the next 80 years.

HBB encodes hemoglobin beta, the protein that fills red blood cells and carries oxygen from your lungs to every tissue in your body. Normal hemoglobin is flexible and smooth. Sickle hemoglobin (from HBB variants) is sticky and polymerizes under low oxygen, forcing red cells into a rigid sickle shape.

Sickle cell disease occurs when someone inherits two copies of the HBB sickle variant,one from each parent. This is much more common in people of African, Mediterranean, and Middle Eastern ancestry; roughly 1 in 500 Black Americans are born with sickle cell disease. Sickle hemoglobin causes red blood cells to get stuck in small vessels, blocking blood flow and triggering severe pain, organ damage, and stroke risk.

In a newborn, finding HBB sickle variants means immediate, aggressive management. If your baby has sickle cell disease (two copies), they need penicillin prophylaxis to prevent sepsis, pain crisis education, and close monitoring. If they’re a carrier (one copy), they’re generally healthy but should know their status for family planning and for understanding why malaria resistance has shaped this gene’s frequency historically.

HLA-DQ2 is an immune system marker,part of the major histocompatibility complex that tells your immune cells which proteins are ‘self’ and which are ‘foreign.’ HLA-DQ2 happens to recognize a component of gluten called deamidated gliadin and flags it as dangerous, triggering an immune attack on the intestinal lining.

HLA-DQ2 is present in roughly 30-40% of the general population,very common. But not everyone with HLA-DQ2 develops celiac disease. The gene is necessary but not sufficient. You need HLA-DQ2 (or its cousin HLA-DQ8) plus gluten exposure plus some additional environmental or genetic trigger.

In a newborn, finding HLA-DQ2 is useful information but not a diagnosis. It means your child is at elevated risk for celiac disease compared to someone without the variant. If celiac runs in your family, you’ll want to monitor for symptoms,chronic diarrhea, failure to thrive, abdominal pain,and can do earlier screening. If your child develops unexplained digestive symptoms later in life, knowing they carry HLA-DQ2 guides your doctor toward celiac testing.